Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) – Analysts at KeyCorp increased their FY2021 EPS estimates for Maravai LifeSciences in a research note issued to investors on Tuesday, May 11th. KeyCorp analyst P. Knight now expects that the company will post earnings of $1.25 per share for the year, up from their previous forecast of $0.83. KeyCorp has a “Overweight” rating and a $46.00 price objective on the stock. KeyCorp also issued estimates for Maravai LifeSciences’ Q4 2021 earnings at $0.32 EPS, FY2022 earnings at $1.30 EPS and FY2023 earnings at $1.40 EPS.
Other research analysts have also issued reports about the company. Credit Suisse Group boosted their target price on Maravai LifeSciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, May 11th. Morgan Stanley boosted their target price on Maravai LifeSciences from $35.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, March 9th. Finally, Zacks Investment Research raised Maravai LifeSciences from a “sell” rating to a “hold” rating and set a $41.00 target price on the stock in a report on Thursday. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $38.67.
Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Monday, May 10th. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.07. The company had revenue of $148.20 million for the quarter, compared to analyst estimates of $135.36 million. The firm’s revenue for the quarter was up 191.2% on a year-over-year basis.
Large investors have recently added to or reduced their stakes in the company. American International Group Inc. bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at $47,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Maravai LifeSciences during the 4th quarter valued at $79,000. Principal Financial Group Inc. bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at $237,000. Diversified Trust Co bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at $240,000. Finally, Quantbot Technologies LP bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at $250,000.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Article: How Do I Invest in Dividend Stocks
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.